A Scalable Human Liver-on-a-Chip Platform for Predictive Safety Assessment.
Summary
Using the OC-Plex microfluidic platform, primary human hepatocytes retained long-term function and enabled multi-parametric detection of acetaminophen hepatotoxicity. Across 17 reference drugs and cosmetic ingredients, the model achieved 85.7% sensitivity, 100% specificity, and 92.3% accuracy, indicating strong potential for scalable, human-relevant safety testing.
Key Findings
- Primary human hepatocytes maintained albumin/urea production and CYP expression over extended culture.
- Detected acetaminophen-induced hepatotoxicity across 6 readouts (albumin, viability, CK18, urea, CYP3A4 activity, mitochondrial function).
- Across 17 compounds (including cosmetic ingredients), achieved 85.7% sensitivity, 100% specificity, and 92.3% accuracy.
Clinical Implications
While preclinical, the platform could accelerate cosmetic and pharmaceutical safety screening, reduce animal testing, and flag hepatotoxic liabilities earlier in development.
Why It Matters
This work addresses cost, scalability, and validation barriers limiting adoption of organ-on-chip methods, delivering quantitative performance against human toxicity benchmarks.
Limitations
- Proof-of-concept with a limited 17-compound panel
- External, inter-laboratory validation and cost-effectiveness analyses are pending
Future Directions
Broaden compound libraries (including diverse cosmetic classes), conduct multi-site validation and blinded challenges, benchmark against human clinical DILI incidence, and engage regulators for qualification.
Study Information
- Study Type
- Case series
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical in-vitro model evaluation without clinical comparators
- Study Design
- OTHER